Catherine Boutsikakis on The Complexities of Hemophilia
Catherine Boutsikakis, Managing Pharmacist – Patient Pharmacy at Cure 4 The Kids Foundation, shared on LinkedIn:
”Thank you Pharmacy Times for the opportunity to discuss the complexities of hemophilia, new treatments available, and the impact on patients and families.”
Watch the full discussion here.
Hemophilia is classified as mild, moderate, or severe based on clotting factor activity, which determines its clinical presentation.
Severe hemophilia is characterized by spontaneous bleeding, especially into joints and muscles, often resulting in chronic pain, limited mobility, and progressive joint damage.
Moderate hemophilia typically leads to bleeding after minor injuries, whereas mild cases usually bleed only with significant trauma or surgical procedures.
Recognizing this spectrum helps clinicians anticipate complications, individualize treatment strategies, and reduce long-term morbidity while preserving quality of life.”
Stay updated with Hemostasis Today.
-
May 28, 2026, 23:47Hussnain Javaid: The Importance of Targeted Examination in Iron Deficiency Anaemia
-
May 28, 2026, 23:47ASH Heads to ASCO26 with Career Opportunities and Global Hematology Leadership
-
May 28, 2026, 23:46Armenia Takes Center Stage in Global Hemophilia Initiative – Yeolyan Hematology and Oncology Center
-
May 28, 2026, 23:45NBCA Joins Global Oncology Leaders at ASCO 2026
-
May 28, 2026, 17:42Nagendra Sungala: International Clinical Trials Day Validates the Work of Our Hematology Clinical Trials Unit
-
May 28, 2026, 17:41Thomas Pincez: Looking for Great Contributions on Pediatric Hematology
-
May 28, 2026, 17:40Masoabi Sefojane: The Real Cost of a Bleeding Disorder Is More Than Cost Alone
-
May 28, 2026, 17:39Zeyad Kholeif: New Publication on Rapid Plaque Progression Leading to STEMI in a Young Athlete
-
May 28, 2026, 17:39Karina Althaus: Results of the SSC Subcommittee International Survey on HIT